Hamilton Choir Singer Hears About First-Ever DNA Therapy and Dares to Dream of One More Verse
The FDA approved the first DNA-based immunotherapy in U.S. history, and one Hamilton choir singer who has lost his voice to throat surgery after throat surgery is daring to hope.
What actually happened
The U.S. Food and Drug Administration on Friday, Oct. 30, 2026, granted accelerated approval to Voceryq, the first plasmid DNA-based immunotherapy ever approved in the United States. The treatment, from Inovio Pharmaceuticals, is for adults with recurrent respiratory papillomatosis, a rare disease caused by human papillomavirus types 6 and 11 that causes small, wart-like growths to form in the airways, most often around the vocal cords.
The disease has no cure, and because the virus persists in the tissue even after growths are removed, patients often need repeated surgeries over many years to keep breathing and speaking. In some cases the growths can spread through the respiratory tract or become cancerous. The FDA said Voceryq targets the root cause of the disease rather than only its symptoms, and has been shown to reduce the burden of surgical intervention.
Voceryq delivers two plasmids — small pieces of DNA, one carrying instructions for specific HPV proteins and the other an immune-boosting molecule called IL-12 — into muscle by injection using the CELLECTRA 5PSP device, which uses brief electrical pulses to help the DNA enter cells. In an open-label trial of 32 adults who had needed at least two surgeries in the prior year, seven of the 26 patients who had needed at least three surgeries needed no surgery at all during the first year after treatment. Because the approval is accelerated, based on an intermediate endpoint, the manufacturer must run post-approval trials to confirm the benefit. The drug received Breakthrough Therapy and Orphan Drug designations.

Meanwhile, in Ohio
HAMILTON, Ohio — Gary Whitaker, 58, has sung tenor in his church choir for twenty years, announced Hamilton Big Blue football games from the press box at Virgil Schwarm Stadium, and, for the last six of those years, has had growths cut out of his throat so often that he schedules the surgeries around the Butler County Fair and the start of choir season. So when his wife Linda showed him the news on Friday that the Food and Drug Administration had approved the first DNA-based immunotherapy in American history — a treatment for the very kind of recurring airway growths that keep stealing his voice — he read the announcement twice, then called his ear, nose and throat doctor in Cincinnati before he had even finished his coffee.
The treatment, called Voceryq, works nothing like the surgeries Whitaker knows. Instead of cutting the growths out again and again, it delivers two tiny pieces of DNA into the muscle with a device that uses brief electrical pulses, training the immune system to attack the virus behind the growths. In the trial, seven of the 26 hardest-hit patients needed no surgery at all in the year after treatment. Whitaker, who once lost his voice for three weeks the month his granddaughter was born, did the math on that one immediately. "Seven out of twenty-six," he said. "Those are better odds than the Bengals have given me most years."
Whitaker knows the approval is an accelerated one, that the drug still has to prove itself in a bigger confirmatory trial, and that it will not be on pharmacy shelves until early next year at the soonest. He is not bothered. He has already told his choir director to save him a spot for the Christmas cantata, told Linda he will celebrate with a three-way at Skyline either way, and told his granddaughter he plans to be the loudest grandpa at her spring concert. "I have spent six years whispering," he said. "I would like to spend the next six singing."

“I have had so many throat surgeries I know the nurses at the surgery center by first name, and they know my order at Skyline. If a shot can mean fewer of those mornings, I will take it and sing about it.”
— Gary Whitaker, Hamilton
“He came home from the ENT with a printout about this DNA thing and read it to me like it was the box score from a Big Blue win. I have never seen him that excited about anything that was not Ohio State-Michigan.”
— Linda Whitaker, Hamilton